Immunotherapy startup CytomX raises $70M; IPO on horizon
The Bay Area immunotherapy player targets PD-L1 and "Probody" drug conjugates. It'll use the $70 million to advance several candidates into the clinic.
What will Novartis’ multiple sclerosis pill cost? (Morning Read)
Swiss drugmaker Novartis just got Food and Drug Administration approval to sell the first pill that can slow the progression of multiple sclerosis. Gilenya will go head-to-head with injectable medicines, including Avonex, Tysabri and Rebif. But how much will the MS pill cost? Novartis won't say, NPR reports.
Balancing the Role of Physicians and AI [Video]
At the ViVE conference in LA, Smarter Technologies Chief Medical Officer Ruben Amarasingham MD talked with Katie Adams about the company's larger goals for AI: to improve the accuracy of data and make healthcare less burdensome for physicians and clinicians.